The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Just use the filter facility.
I've been doing it successfully for a year, as he's no research to share.
Saves a lot of typing about an idiot and the accompanying blood pressure.
Cj62 -
IMO it is an easy thing to do to red ring a set of data that looks essentially complete, and wait until further data is collected and analysed, to understand whether the red ringed data does, or does not, form part of a subsequent data set.
Effectively, - how long is a piece of string?
I know that has happened in areas where I have worked. 😉
Buena Vista - Ref your 09:16 post and AVA027:
"AVA027 - PD-L1 Affimer® / TGF? Trap Bispecific (listed in pipeline at end of July 2021)"
RNS 30th Sep 2021 - Interim Results for the Period Ended 30 June 2021 contains an update for this study.
The two lead programmes are AVA027, a PD-L1/TGF- receptor trap combination, and AVA028, a PD-L1/IL2 bispecific.
***As a result of the clinical data from Merck KGaA and their Bintrafusp alfa (a dual TGF-beta/PD-L1 inhibitor antibody), the Company has decided to pause the AVA027 programme.
This will afford the Company time to further understand the issues arising in the Bintrafusp alfa clinical trials and whether they are related to the trial design, and can therefore potentially be dealt with by better trial design, or whether there is a more fundamental issue with this bispecific combination. ***
In the meantime, the Company is using this pause to focus resources on AVA028 to deliver an Affimer® development candidate as quickly as possible."
++++
There are no references for AVA027 beyond this RNS.
I assume that why its missing from the pipeline at https://avacta.com/therapeutics/pipeline/
Response to Thorno 09:20 post.
From Appointment of Chief Business Officer 19 Dec 2023 RNS:
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"As Chief Business Officer, Simon will work closely with the senior management team and lead commercial strategy and business development activities at this exciting period in the Company's development as compelling clinical data emerges from the AVA6000 phase 1 trial."
"These emerging data give us, for the first time, the opportunity to accelerate ongoing discussions as well as to generate new opportunities through our business development activities aimed at delivering licensing opportunities for the pre|CISIONTM and Affimer® platforms."
Dr Simon Bennett, Chief Business Officer, Avacta Therapeutics commented:
"Avacta is at a pivotal point, having recently announced clinical data that have already begun to generate interest from potential commercial partners. I am delighted to be joining at such an exciting point in the journey of the business, to help the team optimise the commercial opportunities of their technologies and assets."
+++
AS and Simon Bennett laying out the near term Avacta future. - AS's words Thorno/Eggy.
The target being Licensing deals, which will assist in dispelling any medium term financial concerns.
I note Simon uses the word optimise.
Sounds like there are a significant number of commercial opportunities Simon and team need to address, weeding out those that are or become not so attractive, and 'optimising' those with more promise.
Jive_turkey - ref confusion.
This what I have in my notes, with the reference details:
I hope it helps.
AVA028 combines an Affimer PD-L1 antagonist with IL-2 which is a cytokine that plays a signalling role in expanding the number of activated immune cells (T and NK cells). - source Avacta website.
AVA032 - our anti-PD-L1 Affimer® fused to the pro-inflammatory cytokine interleukin 15 (IL-15), displays encouraging efficacy when tested in multiple models of immunomodulation, stimulating a potent immune response and reversing the immunosuppressive tumour microenvironment. - source 05.10.2023 RNS
LLP - If we were preparing to announce a JV for any product under AVCT development, might we remove reference to it from the website, until ready to announce that deal with A. N. Other, even though such a deal was agreed 'in pricipal' beforehand. - Or is that just not Kosher?
As a comparison, I had in mind two documents in two CEO safes, concerning a done deal that was not valid until signed by both parties on a set date, and at the time of signature would be the subject of an RNS by both parties?
A valid method of assuring an agreement isn't an agreement until both parties sign.
++
My last post was to state the one and only time AVA 032 has appeared in an RNS.
This was the last mention of AVA032 in an RNS on the 05.10.2023:
"AVA032 - our anti-PD-L1 Affimer® fused to the pro-inflammatory cytokine interleukin 15 (IL-15), displays encouraging efficacy when tested in multiple models of immunomodulation, stimulating a potent immune response and reversing the immunosuppressive tumour microenvironment. - source 05.10.2023 RNS"
If there were to be a change to the status of efficacy, or a further update on development, it should be announced via an RNS.
That question is better asked after we have seen:
a how much has been spent on developing / marketing YGEN products
b how much has been spent on costs of acquisition
c how much we are making now SLS are involved selling NCYT tests.
Not long to wait to find out.
Another report on the purchase of Lumira DX companies by Roche - with a further info:
03.01.24
https://www.labpulse.com/business-insights/trends-and-finance/mergers-acquisitions/article/15661157/roche-signs-350m-deal-to-buy-poc-technology-from-lumiradx?braze_int_id=64b7b1a59c412b0001d02d21&braze_ext_id=64b7b1a07ab161fb33c6ea4c
Last three paragraphs:
"The sale comes about after a year of transition for LumiraDx. The firm saw its revenues drop sharply in the first quarter of 2023 as it steered its business away from COVID-19 testing. As part of its strategic refocus and cost restructuring, the company announced it would be lay off approximately 40% of its global workforce in April.
In addition, Nasdaq issued a warning to LumiraDx last October that it would be delisted from the stock exchange after its share price fell below $1 for 30 consecutive days. The company said at the time that it planned to appeal.
According to LumiraDx, the proceeds from the sale will be used to repay outstanding amounts under a secured loan agreement; no proceeds will be distributed to the company or shareholders."
+++++
Roche benefitting from diagnostics tech company in financial distress.
Indeed - RNS 07.01.2021 - License Agreement with POINT Biopharma Inc:
"Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT."
++++
Easily affordable for the Lilly, but will be much higher for future licensee's, now AVA6000 is working well.
ValJu
Posted in: NCYT
Posts: 12,265
Price: 55.00
No Opinion
RE: Agm12 Oct 2023 09:32
Voted no across the board and will continue to do so... until thge start being professional about everything :(
+++
Oh no I didn't..
Oh yes you did...
Here's to battering the DHSC in the high court in June for all Novacyt long term sufferers.
SHOW US THE MONEY!!!
Matml74 - FYI:
https://www.jpmorgan.com/content/dam/jpm/commercial-banking/insights/startups-innovation-economy/jpmorgan-chase-q1-2023-biopharma-licensing-and-venture-deals.pdf
Dated April 2023.
Haven't looked through it yet though.
At the bottom of this RNS
"James McCarthy, Acting Chief Executive Officer"
JM still acting.
So IMO JW is waiting to confer CEO status on whomever, when he feels the time is right.
You would think JW would use this opportunity to appoint JM CEO,
but as he hasn't - he must be keeping his options open.
GMCC - That first link has a publication date of Published Date: 07-Nov-2019.
My guess is that the pandemic has since blown predictions for Global Rapid Influenza Diagnostic Tests out the water.
Definitely the wrong time to release this report.
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform
https://finance.yahoo.com/news/roche-enters-definitive-agreement-acquire-213000238.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJMGahkATuIlq-4gl2teRkeyOSGvsuNXYPt1ehQh64wofDiPKSITecQVK-_tXT1Qijg71e47SAan1TG5tAqUz_nIcMJxEasGZyuQDoDtC-PnoE9jEwrx7c_Bwu06oPq3qR-baO_id0eg_AIfMXn8M_LJVQfVdobpydbpkrb_rI9y
Should we vanquish the DHSC in court next June, Novacyt could subsequently become a debt free T/O target to larger entities.
"if you've got concerns about Avacta you can always set them out in an email to Alastair Smith and see what he says."
From now on AS is going to refer to the investormeet Q/A text to reference any and all investor questions.
It should also help with many BP and journalist questions.
This is an Avacta masterstroke.
I too have had blood tests for Prostate issues.
I agree the PSA test is no longer fit for purpose, and find the info contained in this link helpful.
https://www.linkedin.com/feed/update/urn:li:activity:7102625775173935104/
Tony Cooke was CEO of Lab21, - a company in which I invested during his tenure.
I am not invested in Cambridge Clinical Laboratories or any other company mentioned, but will be taking further action as laid out in his post next year.
Apologies in advance for off topic post.
I believe this is the new CBO -
https://www.linkedin.com/in/simon-bennett-a9681b/
If that's correct he has a LinkedIn presence, but he does not use LinkedIn.
Any money due to Yourgene is money Novacyt won't have to invest in Yourgene products.
I'm uncomfortable not knowing how much Novacyt have had to find to invest in Yourgene since acquisition on 08.09.2023.
In the new year, the sp will be partly dependent on the drop in Novacyt funds due to funding the Yourgene business.
I sincerely hope that we see that SLS will have markedly increased sales of Primerdesign / Genesig products since August.
https://www.lse.co.uk/ShareChat.html?ShareTicker=NCYT&share=Novacyt&thread=E1EAFF85-1E40-431F-BDAC-CE460CA056ED&reply=true